Efficacy and Safety of Ipragliflozin in Reducing Body Mass in Patients with Type 2 Diabetes Mellitus:A Systematic Review / 医药导报

ABSTRACT

Objective To systematically evaluate the efficacy and safety of ipragliflozin in reducing the body weight of patients with type 2 diabetes mellitus. Methods Cochrane Library,PubMed,Embase,Medline,CNKI,CBM,VIP and Wanfang data CBM were screened for randomized controlled trials ( RCTs) of type 2 diabetes mellitus treated with ipragliflozin.After the extraction of the data from RCTs and assessing the methodological quality evaluation,the data were analyzed by RevMan5. 3. 5 software. Results A total of 1688 patients were enrolled in 10 RCTs in the study.Meta-analysis showed that the body mass loss [MD＝-1.56,95%CI＝(-1.88,-1.24),P<0.000 01],mass reduction≥5.0%[RR＝2.17,95%CI＝(1.42,3.32),P＝0.000 3], and waist circumference reduction [MD＝-1.16,95%CI＝(-1.58,-0.74),P<0.000 01) were significantly better than those in the placebo group .The incidence of treatment emergent adverse events [RR＝1.05,95%CI＝(0.97,1.14),P＝0.20] and the incidence of serious adverse events [ RR＝0. 56, 95%CI＝( 0. 29, 1. 05), P＝0. 07] were not significant difference between ipragliflozin and placebo. Conclusion Ipragliflozin can significantly reduce the body mass of patients with type 2 diabetes mellitus,and the adverse reactions are mild. It’s necessary to pay attention to the risk of hypoglycemia when ipragliflzin is combined with insulin.